These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1269 related items for PubMed ID: 18985363

  • 1. Analysis of the IDH1 codon 132 mutation in brain tumors.
    Balss J, Meyer J, Mueller W, Korshunov A, Hartmann C, von Deimling A.
    Acta Neuropathol; 2008 Dec; 116(6):597-602. PubMed ID: 18985363
    [Abstract] [Full Text] [Related]

  • 2. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.
    Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, von Deimling A.
    Acta Neuropathol; 2009 Oct; 118(4):469-74. PubMed ID: 19554337
    [Abstract] [Full Text] [Related]

  • 3. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology.
    Capper D, Reuss D, Schittenhelm J, Hartmann C, Bremer J, Sahm F, Harter PN, Jeibmann A, von Deimling A.
    Acta Neuropathol; 2011 Feb; 121(2):241-52. PubMed ID: 21069360
    [Abstract] [Full Text] [Related]

  • 4. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.
    Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A.
    Acta Neuropathol; 2010 Dec; 120(6):707-18. PubMed ID: 21088844
    [Abstract] [Full Text] [Related]

  • 5. IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas.
    Nobusawa S, Watanabe T, Kleihues P, Ohgaki H.
    Clin Cancer Res; 2009 Oct 01; 15(19):6002-7. PubMed ID: 19755387
    [Abstract] [Full Text] [Related]

  • 6. Detection of IDH1 mutations in gliomatosis cerebri, but only in tumors with additional solid component: evidence for molecular subtypes.
    Seiz M, Tuettenberg J, Meyer J, Essig M, Schmieder K, Mawrin C, von Deimling A, Hartmann C.
    Acta Neuropathol; 2010 Aug 01; 120(2):261-7. PubMed ID: 20514489
    [Abstract] [Full Text] [Related]

  • 7. IDH1 mutation in pediatric gliomas: has it a diagnostic and prognostic value?
    Buccoliero AM, Castiglione F, Degl'Innocenti DR, Gheri CF, Genitori L, Taddei GL.
    Fetal Pediatr Pathol; 2012 Oct 01; 31(5):278-82. PubMed ID: 22432788
    [Abstract] [Full Text] [Related]

  • 8. DMBT1 homozygous deletion in diffuse astrocytomas is associated with unfavorable clinical outcome.
    Motomura K, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Pierscianek D, Kim YH, Mariani L, Vital A, Ohgaki H.
    J Neuropathol Exp Neurol; 2012 Aug 01; 71(8):702-7. PubMed ID: 22805772
    [Abstract] [Full Text] [Related]

  • 9. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.
    Takano S, Tian W, Matsuda M, Yamamoto T, Ishikawa E, Kaneko MK, Yamazaki K, Kato Y, Matsumura A.
    Brain Tumor Pathol; 2011 Apr 01; 28(2):115-23. PubMed ID: 21344322
    [Abstract] [Full Text] [Related]

  • 10. IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors.
    Bleeker FE, Lamba S, Leenstra S, Troost D, Hulsebos T, Vandertop WP, Frattini M, Molinari F, Knowles M, Cerrato A, Rodolfo M, Scarpa A, Felicioni L, Buttitta F, Malatesta S, Marchetti A, Bardelli A.
    Hum Mutat; 2009 Jan 01; 30(1):7-11. PubMed ID: 19117336
    [Abstract] [Full Text] [Related]

  • 11. The definition of primary and secondary glioblastoma.
    Ohgaki H, Kleihues P.
    Clin Cancer Res; 2013 Feb 15; 19(4):764-72. PubMed ID: 23209033
    [Abstract] [Full Text] [Related]

  • 12. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.
    Watanabe T, Nobusawa S, Kleihues P, Ohgaki H.
    Am J Pathol; 2009 Apr 15; 174(4):1149-53. PubMed ID: 19246647
    [Abstract] [Full Text] [Related]

  • 13. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
    Korshunov A, Meyer J, Capper D, Christians A, Remke M, Witt H, Pfister S, von Deimling A, Hartmann C.
    Acta Neuropathol; 2009 Sep 15; 118(3):401-5. PubMed ID: 19543740
    [Abstract] [Full Text] [Related]

  • 14. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients.
    Sonoda Y, Kumabe T, Nakamura T, Saito R, Kanamori M, Yamashita Y, Suzuki H, Tominaga T.
    Cancer Sci; 2009 Oct 15; 100(10):1996-8. PubMed ID: 19765000
    [Abstract] [Full Text] [Related]

  • 15. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
    Gravendeel LA, Kloosterhof NK, Bralten LB, van Marion R, Dubbink HJ, Dinjens W, Bleeker FE, Hoogenraad CC, Michiels E, Kros JM, van den Bent M, Smitt PA, French PJ.
    Hum Mutat; 2010 Mar 15; 31(3):E1186-99. PubMed ID: 20077503
    [Abstract] [Full Text] [Related]

  • 16. Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.
    Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Kayama T, Shibui S.
    Brain Tumor Pathol; 2012 Oct 15; 29(4):183-91. PubMed ID: 22790483
    [Abstract] [Full Text] [Related]

  • 17. Telomerase activity and alterations in telomere length in human brain tumors.
    Hiraga S, Ohnishi T, Izumoto S, Miyahara E, Kanemura Y, Matsumura H, Arita N.
    Cancer Res; 1998 May 15; 58(10):2117-25. PubMed ID: 9605755
    [Abstract] [Full Text] [Related]

  • 18. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.
    Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.
    Acta Neuropathol; 2015 Jan 15; 129(1):133-46. PubMed ID: 25427834
    [Abstract] [Full Text] [Related]

  • 19. CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas.
    Sahm F, Koelsche C, Meyer J, Pusch S, Lindenberg K, Mueller W, Herold-Mende C, von Deimling A, Hartmann C.
    Acta Neuropathol; 2012 Jun 15; 123(6):853-60. PubMed ID: 22588899
    [Abstract] [Full Text] [Related]

  • 20. IDH1 mutations in diffusely infiltrating astrocytomas: grade specificity, association with protein expression, and clinical relevance.
    Thota B, Shukla SK, Srividya MR, Shwetha SD, Arivazhagan A, Thennarasu K, Chickabasaviah YT, Hegde AS, Chandramouli BA, Somasundaram K, Santosh V.
    Am J Clin Pathol; 2012 Aug 15; 138(2):177-84. PubMed ID: 22904127
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 64.